Q-omics provides the consensus-scored NNT profile across patient tissues and cancer cell-line models. NNT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NNT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NNT RNA expression shows 18,965 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where NNT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NNT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NNT survival associations across molecular data types. NNT RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NNT RNA expression–survival associations across cancer types. High NNT expression shows unfavorable associations in UVM and CESC, but favorable associations in KIRC, KIRP, HNSC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NNT RNA expression.
This table summarizes NNT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NNT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NNT shows lower tumor expression in KIRC, THCA and COAD and higher tumor expression in LUAD, KICH and LUSC. The KIRC box plot shows higher NNT RNA expression in normal versus tumor tissue (log2 FC = −1.350, t-test p < 0.001).
This table shows molecular features associated with NNT in patient tissues and cancer cell lines. In patient samples, NNT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NNT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
